Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.83 Consensus Target Price from Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have been assigned an average rating of "Buy" from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $8.83.

Several equities analysts have recently commented on the company. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, October 25th. JMP Securities reiterated a "market outperform" rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Finally, Leerink Partners raised their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Friday, October 25th.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of large investors have recently bought and sold shares of AQST. Financial Advocates Investment Management boosted its holdings in shares of Aquestive Therapeutics by 14.7% in the 3rd quarter. Financial Advocates Investment Management now owns 39,000 shares of the company's stock valued at $194,000 after acquiring an additional 5,000 shares during the last quarter. nVerses Capital LLC purchased a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $28,000. SG Americas Securities LLC lifted its holdings in shares of Aquestive Therapeutics by 58.9% in the 3rd quarter. SG Americas Securities LLC now owns 25,619 shares of the company's stock valued at $128,000 after buying an additional 9,496 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics in the second quarter worth about $27,000. Finally, PFG Investments LLC raised its position in Aquestive Therapeutics by 22.9% during the second quarter. PFG Investments LLC now owns 59,000 shares of the company's stock valued at $153,000 after acquiring an additional 11,000 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock traded up $0.03 during mid-day trading on Friday, reaching $5.52. 1,314,196 shares of the stock traded hands, compared to its average volume of 1,744,886. The stock has a market capitalization of $502.65 million, a PE ratio of -16.06 and a beta of 2.85. The business's 50-day moving average is $4.86 and its 200-day moving average is $3.80. Aquestive Therapeutics has a 12-month low of $1.41 and a 12-month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period last year, the business posted ($0.10) EPS. Equities analysts anticipate that Aquestive Therapeutics will post -0.48 EPS for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.